autologous cell-based delivery
12-008521
Phase 1 mab completed
Quick answer
autologous cell-based delivery for Hypoplastic Left Heart Syndrome is a Phase 1 program (mab) at Regen BioPharma Inc with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Regen BioPharma Inc
- Indication
- Hypoplastic Left Heart Syndrome
- Phase
- Phase 1
- Modality
- mab
- Status
- completed